<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01839773</url>
  </required_header>
  <id_info>
    <org_study_id>107CS-3</org_study_id>
    <nct_id>NCT01839773</nct_id>
  </id_info>
  <brief_title>A Phase 3 Study to Compare Efficacy and Safety of DHP107 Versus Taxol® in Patients With Metastatic or Recurrent Gastric Cancer After Failure of First-line Chemotherapy</brief_title>
  <acronym>DREAM</acronym>
  <official_title>A Randomized, Open, Multicenter Phase 3 Study for Efficacy and Safety Assessment of DHP107 (Oral Paclitaxel) vs. Taxol® in Patients With Metastatic or Recurrent Gastric Cancer After Failure of First-line Chemotherapy With Fluoropyrimidine +/- Platinum</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Daehwa Pharmaceutical Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Daehwa Pharmaceutical Co., Ltd.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of this study is to evaluate the efficacy and safety of DHP107 (Oral
      paclitaxel) in comparison to Taxol®(IV paclitaxel) in Patients With Metastatic or Recurrent
      Gastric Cancer After Failure of 1st Line Chemotherapy With Fluoropyrimidine +/- Platinum.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>March 2013</start_date>
  <completion_date type="Actual">August 2015</completion_date>
  <primary_completion_date type="Actual">August 2015</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Progression Free Survival (PFS)</measure>
    <time_frame>Participants will be followed until progression, an expected average of 4 months.</time_frame>
    <description>Progression Free Survival (PFS) is defined as the time From date of randomization until the date of first documented progression or death, assessed up to 24 months.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall Survival (OS)</measure>
    <time_frame>Until 6 months after the last participant is enrolled, assessed up to 24 months.</time_frame>
    <description>Overall survival (OS) is defined as the time from the date of inclusion to the date of death, regardless of the cause of death.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Response Rate (ORR)</measure>
    <time_frame>Participants will be followed every 6 weeks until progression, an expected average of 4 months.</time_frame>
    <description>Overall Response Rate (ORR) is defined by Response Evaluation Criteria in Solid Tumors (RECIST) (v.1.1) criteria.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety</measure>
    <time_frame>Up to 24 months</time_frame>
    <description>Number and Description of Adverse Events</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">238</enrollment>
  <condition>Stage IV Gastric Cancer</condition>
  <arm_group>
    <arm_group_label>DHP107 (oral paclitaxel)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>DHP107 (oral paclitaxel) will be administered weekly as second line chemotherapy in patients with metastatic or recurrent gastric cancer after failure of first line chemotherapy with fluoropyrimidine +/- platinum.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Taxol® (IV paclitaxel)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Taxol® (IV paclitaxel) will be administered 3-weekly as second line chemotherapy in patients with metastatic or recurrent gastric cancer after failure of first line chemotherapy with fluoropyrimidine +/- platinum.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Paclitaxel</intervention_name>
    <description>Oral administration on day 1,8,15 of 4-week cycle until progression, unacceptable toxicity or withdrawal of informed concent</description>
    <arm_group_label>DHP107 (oral paclitaxel)</arm_group_label>
    <other_name>DHP107</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Paclitaxel</intervention_name>
    <description>Premedication, IV infusion on day 1 of 3-week cycle until progression, unacceptable toxicity or withdrawal of informed concent</description>
    <arm_group_label>Taxol® (IV paclitaxel)</arm_group_label>
    <other_name>Taxol®</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. ≥20 years of age

          2. Histologically or cytologically confirmed unresectable, recurrent or metastatic
             gastric cancer

          3. Failure of a first line therapy with fluoropyrimidine +/- platinum for metastatic or
             recurrent disease.(Adjuvant chemotherapy is not considered as a first line
             chemotherapy unless recurrence developed within 6 months of completion of adjuvant
             therapy.)

          4. Adequate bone marrow, liver and renal functions

          5. INR ≤ 2.0

          6. ECOG performance status ≤ 2

          7. Neuropathy grade ≤ 1

          8. Life expectancy of at least 3 months

          9. Measurable lesion according to RECIST version 1.1 on CT scan

         10. Written informed consent

         11. Patients of child bearing age have to agree to the usage of adequate contraception
             from before the registration to the study, during the participation period and 90 days
             after the end of treatment. Female of child bearing age has to show negative for urin
             pregnancy test within 7 days from beginning of the start of administration. Amenorrhea
             status has to be sustained for at least 12 months to be considered non-pregnant in
             case of postmenstrual women.

        Exclusion Criteria:

          1. Major infectious disease, neurological disorder, or bowel obstruction.

          2. Patients with CNS metastases(confirmed through brain imaging if there are symptoms)

          3. Patient diagnosed with another cancer type (except non-melanoma skin cancer, cervical
             cancer, or any other cancer that did not recur or metastasized for more than 5 years
             and considered as complete remission can be registered)

          4. Patient who received radiation therapy within past 2 weeks or who had major surgery
             including organ resection within past 4 weeks from random assignment date

          5. Patient with the history of failure to the taxane chemotherapy

          6. Patient who need chronic concomitant use of P glycoprotein, immune suppressor, proton
             pump inhibitor, or H2-receptor antagonist during the period of clinical trial

          7. Chronic treatment using steroid (except oral, local injection, or for externally
             applied) or other immune suppressor

          8. Patient with myocardial infarction, congestive heart failure, arrhythmia showing
             abrupt change in the ECG, severe or unstable angina, or other serious heart disease

          9. Patient with other serious internal disease (chronic obstructive or chronic inhibitory
             lung disease including shortness of breathe at rest due to all reasons, uncontrollable
             diabetes and hypertension)

         10. History of abuse of a drug or alcohol within 3 months

         11. Lactating or pregnant women, or patient (or spouse) who has no intension of using, or
             cannot use very effective mean of contraception

         12. Patient who has or is suspected to have problem in bile acid secretion

         13. Patient with active gastrointestinal bleeding, or taking oral anti- vitamine K (With
             the exception of low dose of Warfarin and acetylsalicylic acide when INR≤2.0)

         14. History of serious hypersensitive reaction to the main ingredient or the excipient of
             the investigational drug

         15. History of being seropositive for HIV (HIV test is not a prerequisite).

         16. Patients with gastrointestinal dysfunction or on enteral feeding

         17. Other patients who are deemed inadequate to participate in the clinical trial by the
             investigator
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Inje University Haeundae Paik Hospital</name>
      <address>
        <city>Busan</city>
        <zip>612-896</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kyungpook National University Medical Center</name>
      <address>
        <city>Daegu</city>
        <zip>702-210</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>National Cancer Center</name>
      <address>
        <city>Goyang-si, Gyeonggi-do</city>
        <zip>410-769</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chonnam National University Hwasun Hospital</name>
      <address>
        <city>Jeollanam-do</city>
        <zip>519-763</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Seoul National University Bundang Hospital</name>
      <address>
        <city>Seongnam-si, Gyeonggi-do</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Yonsei University Severance Hospital</name>
      <address>
        <city>Seoul</city>
        <zip>120-752</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Samsung Medical Center</name>
      <address>
        <city>Seoul</city>
        <zip>135-710</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Yonsei University Gangnam Severance Hospital</name>
      <address>
        <city>Seoul</city>
        <zip>135-720</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Seoul St. Mary's Hospital</name>
      <address>
        <city>Seoul</city>
        <zip>137-701</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Asan Medical Center</name>
      <address>
        <city>Seoul</city>
        <zip>138-736</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Korea University Guro Hospital</name>
      <address>
        <city>Seoul</city>
        <zip>152-703</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ajou University Hospital</name>
      <address>
        <city>Suwon</city>
        <zip>443-380</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>August 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 12, 2013</study_first_submitted>
  <study_first_submitted_qc>April 22, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 25, 2013</study_first_posted>
  <last_update_submitted>August 9, 2015</last_update_submitted>
  <last_update_submitted_qc>August 9, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 11, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Stomach Neoplasms</keyword>
  <keyword>Cancer of Stomach</keyword>
  <keyword>Gastric Cancer</keyword>
  <keyword>Gastric Neoplasms</keyword>
  <keyword>Neoplasms, Gastric</keyword>
  <keyword>Neoplasms, Stomach</keyword>
  <keyword>Stomach Cancer</keyword>
  <keyword>paclitaxel</keyword>
  <keyword>Taxol</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Stomach Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Paclitaxel</mesh_term>
    <mesh_term>Albumin-Bound Paclitaxel</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

